Use SGLT2is (dapagliflozin, empagliflozin) and GLP-1RAs (semaglutide) as standard therapy. Dual GIP/GLP-1RAs (tirzepatide) for obesity/metabolic control. Optimize heart failure and ASCVD management. The gene discussed is GIP; the disease is heart failure.